According to Zacks, “Prima Biomed Ltd is a biotechnology company focused on developing oncology therapies in the field of immunotherapy. The Company’s key product candidates in development include CVac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumor types, and an oral formulation for the Human Papilloma Virus. Prima Biomed Ltd is based in Sydney, Australia. “
PBMD has been the subject of several other research reports. FBR & Co restated a buy rating on shares of Prima BioMed in a report on Friday, August 26th. Roth Capital restated a buy rating and set a $6.00 price target on shares of Prima BioMed in a report on Friday, August 26th. Maxim Group restated a buy rating on shares of Prima BioMed in a report on Wednesday, June 8th. Finally, HC Wainwright reaffirmed a buy rating on shares of Prima BioMed in a research note on Wednesday, June 22nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Prima BioMed presently has an average rating of Buy and a consensus price target of $4.20.
Shares of Prima BioMed (NASDAQ:PBMD) opened at 0.88 on Thursday. Prima BioMed has a 52-week low of $0.72 and a 52-week high of $1.54. The company has a 50-day moving average price of $0.87 and a 200-day moving average price of $0.95. The company’s market cap is $60.47 million.
About Prima BioMed
Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Company’s main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prima BioMed Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.